# BSX — Boston Scientific · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** BSX  
**Sources:** 28  
**Published:** 2026-08-09  
**Canonical:** https://app.k3vl4r.com/research/deep-research-bsx-boston-scientific-catalysts-narrative-risks-1643

---

# Boston Scientific (BSX) — Research Summary as of August 6, 2026

## Key Recent Catalysts (Last ~1–3 Months)

### Q2 2026 Earnings Beat (July 29, 2026)
The most significant recent catalyst was Boston Scientific's Q2 2026 earnings report, released on July 29, 2026. The company generated **net sales of $5.442 billion**, representing **7.5% reported growth** and **7.0% organic growth** year-over-year [[1]](https://news.bostonscientific.com/2026-07-29-Boston-Scientific-announces-results-for-second-quarter-2026). The results exceeded Wall Street expectations, with the company delivering an **earnings surprise of +3.61%** and a **revenue surprise of +1.07%** for the quarter ended June 2026 [[4]](https://www.zacks.com/stock/research/BSX/all-news). The adjusted EPS came in at $0.835 against market expectations of $0.86 [[7]](https://www.tipranks.com/stocks/bsx/earnings), though it should be noted that the positive earnings surprise percentage reported in [[4]](https://www.zacks.com/stock/research/BSX/all-news) may reflect a different consensus figure or adjusted metric, so there is some ambiguity in the exact beat magnitude.

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-bsx-boston-scientific-catalysts-narrative-risks-1643 (free to sign up)._